•
Dec 31, 2019
Merus Q4 2019 Earnings Report
Merus reported financial results for Q4 and full year 2019 and provided a business update.
Key Takeaways
Merus N.V. announced financial results for the fourth quarter and full year ended December 31, 2019. The company's cash, cash equivalents and marketable securities totaled $241.8 million at the end of 2019, and the company expects to be funded into 2022.
Encouraging, early clinical activity in zenocutuzumab program for NRG1+ cancers.
Phase 1/2 eNRGy trial enrollment continues for NRG1+ cancers.
Phase 2 interim analysis reported for metastatic breast cancer trial.
Cash runway extended, Merus expects to be funded into 2022 through first follow-on offering.
Merus
Merus
Merus Revenue by Segment
Forward Guidance
Based on the Company’s current operating plan, the Company expects its existing cash, cash equivalents and investments will be sufficient to fund its operations into 2022.